Demographic and clinical characteristics in patients with AQP4+NMOSD and MS at MRI-1 in study1
| AQP4+NMOSD (n=36) | RRMS (n=60) | p value | |
| Demographic | |||
| Female (%) | 32/36 (88.9%) | 46/60 (76.7%) | 0.18 |
| Age (years) | 54.5 (19.0) (34–77) | 40.5 (13.0) (17–67) | <0.001* |
| Clinical | |||
| Disease duration (years) | 6.3 (14.9) (0.25–42.9) | 8.3 (11.2) (0.42–34.7) | 0.14 |
| EDSS score | 4.5 (4.0) (1.0–9.0) | 2.0 (3.0) (0.0–7.5) | 0.006* |
| ARR from disease onset | 0.65 (0.59) (0.20–4.0) | 0.54 (0.53) (0.06–2.8) | 0.36 |
| Months from last attack | 20.6 (33.6) (2.4–48.0) | 32.9 (44.3) (1.1–207) | 0.81 |
| Months from DMD initiation | 12.6 (18.3) (1.2–68.1) | 17.8 (34.1) (0–172) | 0.29 |
| Oligoclonal bands positivity | 5/27 (18.5%) | 33/49 (67.3%) | <0.001* |
| Number of patients with a history of | |||
| Optic neuritis | 25/36 (69.4%) | ||
| Myelitis | 30/36 (83.3%) | ||
| Long cord lesion | 21/36 (58.3%) | ||
| Brain stem lesion | 9/36 (25%) | ||
| Area postrema syndrome | 2/36 (5.6%) | ||
| Cerebral syndrome | 6/36 (16.7%) | ||
| DMD | |||
| Interferonβ−1a | 0 | 16 | |
| Interferonβ−1b | 0 | 10 | |
| Fingolimod | 0 | 22 | |
| Dimethyl fumarate | 0 | 5 | |
| Natalizumab | 0 | 2 | |
| Prednisolone | 25 | 0 | |
| Prednisolone+azathioprine | 5 | 0 | |
| Prednisolone+eculizumab | 1 | 0 | |
| None | 5 | 5 |
Data are presented as median number (%) or (IQR; range). *p < 0.05. Months from DMD initiation indicate period between the start of the same DMD given before MRI-1 and the date MRI-1 was performed.
AQP4+NMOSD, anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease; ARR, annual relapse rate; DMD, disease-modifying drug; EDSS, Kurtzke’s Expanded Disability Status Scale.